Article Text

Download PDFPDF

5PSQ-084 Assessing quality of life of patients with severe asthma measured by patient reported outcomes
  1. M Muñoz García:1,
  2. H Martínez-Barros1,
  3. P Guijarro-Martínez1,
  4. A Santamaria-Gadea2,
  5. A de-Andrés-Martín3,
  6. D González-de-Olano1,
  7. A Morales-Tirado4,
  8. D Antolín-Amérigo5,
  9. S Sánchez-Cuéllar6,
  10. AM Alvarez Diaz1
  1. 1Hospital Universitario Ramon Y Cajal, Pharmacy, Madrid, Spain
  2. 2Hospital Universitario Ramon Y Cajal, Otorhinolaringology, Madrid, Spain
  3. 3Hospital Universitario Ramon Y Cajal, Inmunology, Madrid, Spain
  4. 4Hospital Universitario Ramon Y Cajal, Pediatrics Service, Madrid, Spain
  5. 5Hospital Universitario Ramon Y Cajal, Allergy, Madrid, Spain
  6. 6Hospital Universitario Ramon Y Cajal, Neumology, Madrid, Spain


Background and Importance Severe asthma, which affects approximately 5-10% of people with asthma, is a heterogenous, chronic and complex disease. It usually has a negative physical, mental, emotional and social impact.

Aim and Objectives To analyse quality of life of patients with severe asthma currently treated with biological drugs using Patient Reported Outcomes Measures (PROM).

To identify the domains and specific questions most frequently altered, by using mini-AQLQ.Material and Methods

A descriptive cross-sectional study between April-May 2022 in a tertiary hospital was carried out. Adult patients with severe asthma on active treatment with a biological drug for at least one year who provided informed consent were included.

Electronic medical records were reviewed to obtain:

  • Age, sex

  • Number of asthma-associated comorbidities

  • FEV1 and FEV/FVC

A telephone interview was also conducted to record the PROMs:

  • Mini-AQLQ (maximum score: 7)

  • EQ5D-5L (maximum score:1) (with Visual analogue scale, score 0-100 (VAS))

Results Fifty-five patients who met the inclusion criteria were identified. 38 who agreed to participate were located. Median age was 65 years (56-71.5) and 60.5% (23) were female. Median number of asthma-related comorbidities was 2.5 (1-4). FEV1 and FEV/CVF were 76.3% (SD=3.2) and 69% (SD=1.3) respectively.

The mean score for the EQ5D-5L was 0.924 (0.818-1), while the median VAS was 70 (60-85).

The average score for the mini-AQLQ was 6.1. By domains, environmental had the worst mean (5 (4.3-6.3)), followed by limitation of activities (6.1 (5.5-6.7)), symptoms (6.2 (5.8-7)) and emotional (7 (5.3-7)).

Three (0.8%) patients did not have any disturbances in the responses, but a 81.6% (31) had altered limitation of activities,79.3% (29) environmental, 73.7% (28) symptoms and 55.3% (21) emotional.

Specifically, the question that most frequently receive a score below 7 was ‘did you feel that tobacco smoke bothered you or did you have to avoid a place because of tobacco smoke?’ in 76.3% (29) patients.

Conclusion and Relevance The quality of life of patients with severe asthma treated with biological drugs is good, according to specific asthma questionnaires used as PROM, although few patients do not have any altered sphere.

The most altered sphere was environmental. Tobacco is considered a major threat.

Conflict of Interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.